The Peptide Comment Window Is Open, and Narrower Than It Looks

The HHS peptide enforcement policy completed its move onto the formal record on October 30: published in the Federal Register, assigned a docket, and opened for public comment through November 13. Two days after the policy first surfaced, the process question has replaced the policy question: what does this comment window actually decide? [1][3]

What ran on October 30

The HHS notice of availability for its 503A peptide enforcement discretion policy was published in the October 30 Federal Register at 91 FR 68526, under docket HHS-OASH-2026-0496. The Federal Register page now states that comments on the document are being accepted at Regulations.gov, and the notice sets written comments due two weeks after the date of publication. The docket sets the exact deadline at 11:59 PM Eastern on November 13, with both the policy and the notice itself open for comment. [1][3]

The policy text did not change in publication. The document the notice points to is the same draft covered here on October 29: a statement that HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding with six named peptides, under ten stated conditions, framed as a step "to expand and improve patient access." [1][2]

What the comment period does not decide

A notice of availability is not a rule. The publication carries no effective date and amends nothing in the Code of Federal Regulations, and the policy repeats that it establishes no rights and does not bind HHS or the public. [1][3]

Comments on this docket will not decide whether BPC-157, TB-500, epitalon, KPV, MOTS-c or semax join the 503A bulks list. That list is set by FDA rulemaking, a separate notice-and-comment process that typically runs months to years, and the notice says only that future rulemakings may propose adding some or all of the six. The bulks list in federal regulation today contains six substances, none of them peptides. [1][3][4]

The quiet docket

Nobody has taken the window up yet, at least publicly. As of early October 31, the count of posted comments on the docket was zero, according to Peptide Policy Watch's check of the regulations.gov public data, which notes that posted counts trail what has been submitted because comments appear only after agency review. [3]

Law firm analysis published alongside the publication underscores the interim posture: Foley & Lardner notes the policy applies only when all of its stated circumstances are met, and that HHS says it may revisit the policy if it identifies a safety signal or product quality issues. [4]

What it signals

The administration has moved the peptide policy from announcement to formal publication without changing a word, and opened the shortest meaningful step in the process. The larger decision, whether any of the six substances earns a permanent place on the bulks list, sits in a rulemaking that has not been proposed yet. [1][3][4]

The comment window decides nothing by itself. It feeds the record for a rule that has not been proposed yet.

What it means for a clinic: If compounded peptides touch your practice, these two weeks are the formal chance to be heard, on the docket at regulations.gov under HHS-OASH-2026-0496. Weigh in on the conditions if you have operational evidence; that record is what later rulemaking reads. For everyone else, the working frame from October 29 still holds: a draft, non-binding statement of enforcement intent around six named substances under ten conditions, with a final answer still ahead. An open docket is not an approval, and a quiet one is not a consensus.